logo Hematology/Oncology Research Studies: Open for Enrollment Date: 05/27/20


Pazopanib in Combination with Irinotecan and Temozolomide for Children and Young Adults with Relapsed or Refractory Sarcoma

NCT#/Phase: NCT03139331
Phase 1
IRB#: 2017-039
Description: This early phase study will evaluate the maximum tolerated dose and toxicities of oral antiogenic agent pazopanib in combination with fixed doses of irinotecan and temozolomide for children and young adults with relapsed or refractory sarcoma.
Inclusion: Individuals who are between 6-30 years of age at the time of study enrollment with histologic verification of Ewing sarcoma/peripheral PNET, Osteosarcoma, Rhabdomyosarcoma, Non-rhabdomyosarcoma soft tissue sarcoma, or Desmoplastic small round cell tumor who have ave either measurable or evaluable disease.
Enrollment Status: Open for enrollment
Sponsor: University of California, San Francisco
Principal Investigator(s): Jennifer Michlitsch, MD
Contact(s): Jennifer Michlitsch, MD
Anu Agrawal, MD
Study Link: https://clinicaltrials.gov/ct2/show/NCT03139331

UCSF Benioff Children's Hospital Oakland • 747 52nd Street, Oakland, California 94609 &bull Phone: (510) 428-3000